试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-21
CIMER: Combined Immunotherapies in Metastatic ER+ Breast Cancer
编号:NCT04220476登记状态:入组前撤回企业 / 申办者:Weill Medical College of Cornell University
药物 / 成分:Stereotactic Body Radiation Therapy (SBRT) (50GY in 5 fractions)、Letrozole 2.5Mg Tab、Palbociclib 125mg
登记的停止原因(原文):Initiating a new study with revised Statistics.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-18
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
编号:NCT00226746登记状态:入组前撤回企业 / 申办者:New York Presbyterian Brooklyn Methodist Hospital
药物 / 成分:Paclitaxel and gemcitabine
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-18
COMPOUND (INN): HOE490O - GLIMEPIRIDE / METFORMIN HCl (Amaryl® M)0 (Glimepiride/Metformin Hydrochloride Immediate Release Combination Tablet) in Fed Conditions in Healthy Male and/or Female Subjects.
编号:NCT02395237登记状态:入组前撤回企业 / 申办者:Pharmaceutical Research Unit, Jordan
药物 / 成分:: Amaryl® M IR 2/1000
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-18
Ictal SPECT With Intra-arterial Injection
编号:NCT02513992登记状态:入组前撤回企业 / 申办者:Universitaire Ziekenhuizen KU Leuven
药物 / 成分:intra-arterial injection of tracer、99m-Technetium Ethyl Cysteinate Dimer、intra-arterial catheter、pressure injector
登记的停止原因(原文):no patient met inclusion criteria
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease
编号:NCT02500784登记状态:入组前撤回企业 / 申办者:Palo Alto Veterans Institute for Research
药物 / 成分:Formoterol A、Formoterol B (placebo)
登记的停止原因(原文):Funding ran out before study started, prior PI left institution.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Serratus Anterior Muscle Plane Block vsThoracic Paravertebral Block For Unilateral Mastectomies
编号:NCT02822196登记状态:入组前撤回企业 / 申办者:The University of Texas Health Science Center, Houston
药物 / 成分:Lidocaine、Bupivacaine
登记的停止原因(原文):Critical study personnel left the institution
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Study of Sodium Bicarbonate in Restoring Blocked Catheters
编号:NCT03348826登记状态:入组前撤回企业 / 申办者:University Health Network, Toronto
药物 / 成分:Sodium Bicarbonate 8.4% Solution for Injection、Alteplase Injectable Solution
登记的停止原因(原文):No participants were enrolled
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of CDX 6114 in PKU Patients
编号:NCT04256655登记状态:入组前撤回企业 / 申办者:Société des Produits Nestlé (SPN)
药物 / 成分:cohort 1 0.225g、Cohort 2 0.75g、Cohort 3 2.25 g
登记的停止原因(原文):study product composition to move from liquid to solid
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Treatment of Lung Injury From COVID-19 Infection With Intravenous Sodium Nitrite
编号:NCT04401527登记状态:入组前撤回企业 / 申办者:Hope Pharmaceuticals
药物 / 成分:Sodium Nitrite、Normal Saline
登记的停止原因(原文):No recruitment
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2020-09-16
Growth Hormone in Obese Cases With Covid-19
编号:NCT04532554登记状态:入组前撤回企业 / 申办者:ClinAmygate
药物 / 成分:Growth Hormone、Placebo
登记的停止原因(原文):No participants enrolled
查看官方原始记录 ↗